Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.

[1]  Yajing Liu,et al.  Design, synthesis, and biological evaluation of novel 4‐phenoxypyridine derivatives as potential antitumor agents , 2019, Archiv der Pharmazie.

[2]  M. Ghate,et al.  Recent advances in the discovery of small molecule c-Met Kinase inhibitors. , 2018, European journal of medicinal chemistry.

[3]  P. Gong,et al.  Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors. , 2017, Bioorganic & medicinal chemistry.

[4]  Linxiao Wang,et al.  Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. , 2017, European journal of medicinal chemistry.

[5]  Jinming Pan,et al.  Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. , 2017, Bioorganic & medicinal chemistry.

[6]  Wen-long Huang,et al.  Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. , 2017, Bioorganic chemistry.

[7]  Jinxing Hu,et al.  Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors. , 2016, European journal of medicinal chemistry.

[8]  X. Zhai,et al.  Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors. , 2016, European journal of medicinal chemistry.

[9]  Manish Kumar Jeengar,et al.  Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. , 2015, Experimental and molecular pathology.

[10]  A. Kamal,et al.  Design and Synthesis of C3‐Pyrazole/Chalcone‐Linked Beta‐Carboline Hybrids: Antitopoisomerase I, DNA‐Interactive, and Apoptosis‐Inducing Anticancer Agents , 2014, ChemMedChem.

[11]  P. Gong,et al.  Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents. , 2014, European journal of medicinal chemistry.

[12]  Wei Huang,et al.  Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[13]  Mallika Alvala,et al.  Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells , 2014, Apoptosis.

[14]  Yechun Xu,et al.  Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. , 2014, ACS medicinal chemistry letters.

[15]  Jae Cheol Lee,et al.  MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.

[16]  Shuang Liu,et al.  Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. , 2013, European journal of medicinal chemistry.

[17]  K. Rex,et al.  Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. , 2012, Journal of medicinal chemistry.

[18]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[19]  Yao Dai,et al.  BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitro , 2010, Molecular Cancer Therapeutics.

[20]  Stephen K Burley,et al.  SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo , 2009, Molecular Cancer Therapeutics.

[21]  K. Yamaguchi,et al.  Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.

[22]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[23]  Ken S Lau,et al.  Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. , 2008, BioTechniques.

[24]  C. Tepper,et al.  The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7 , 2006, Oncogene.

[25]  J. Guan,et al.  Wound-healing assay. , 2005, Methods in molecular biology.

[26]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[27]  Toshikazu Nakamura,et al.  Acquisition of Invasive Phenotype in Gallbladder Cancer Cells via Mutual Interaction of Stromal Fibroblasts and Cancer Cells as Mediated by Hepatocyte Growth Factor , 1996, Japanese journal of cancer research : Gann.

[28]  G. V. Vande Woude,et al.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network , 1996, Molecular and cellular biology.

[29]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.